- Report
- March 2024
- 143 Pages
Global
From €3770EUR$3,899USD£3,238GBP
- Report
- November 2023
- 138 Pages
Global
From €2416EUR$2,499USD£2,075GBP
- Report
- February 2024
- 182 Pages
Global
From €4737EUR$4,900USD£4,069GBP
- Report
- February 2024
- 132 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- March 2022
- 124 Pages
Global
From €4302EUR$4,450USD£3,695GBP
- Book
- July 2019
North America
Hyperthyroidism is a condition in which the thyroid gland produces an excessive amount of thyroid hormones. It is a common endocrine disorder that affects people of all ages, genders, and ethnicities. Symptoms of hyperthyroidism can include weight loss, increased appetite, rapid heart rate, anxiety, irritability, and fatigue. Treatment options for hyperthyroidism include antithyroid medications, radioactive iodine, and surgery.
The hyperthyroidism market is a subset of the larger endocrinology market. It is a growing market, driven by increasing prevalence of the condition, technological advancements, and the availability of new treatments. The market is expected to grow at a steady rate over the next few years.
Some companies in the hyperthyroidism market include AbbVie, Inc., AstraZeneca, GlaxoSmithKline, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi, and Takeda Pharmaceutical Company Limited. Show Less Read more